We are working towards a transplant of insulin producing cells combined with nanosensors for diabetes that is so safe and effective we would put it in our own bodies and the bodies of people we love. We believe our ability to create more robust and controlled insulin producing cell transplants that can be monitored in vivo over time will revolutionize the current clinical landscape for diabetes and cell replacement therapy.
| Website | http://minutia.co |
| Revenue | $6.4 million |
| Employees | 25 (13 on RocketReach) |
| Founded | 2021 |
| Industry | Biotechnology |
| Keywords | Diabetes Treatment, Cell Therapy, Nanosensors, Biosensors, Diabetes Management, Diabetes Research, Biological Sensors, Regenerative Medicine, Nanotechnology, Biotechnology, Medical Technology, Therapeutic Devices, Biomedical Engineering, Innovative Therapies, Advanced Therapies, Drug Delivery, Precision Medicine, Stem Cell Technology |
| Competitors | Slack, Salesforce, HubSpot, Zoho, monday.com, Asana, ClickUp, Airtable, Pipedrive, Trello +46 more (view full list) |
Looking for a particular Minutia employee's phone or email?
The Minutia annual revenue was $6.4 million in 2026.
Catherine Digovich is the CEO and Co-Founder of Minutia.
13 people are employed at Minutia.
Minutia is based in Oakland, California.